Search the Newsreel

Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Jupiter Neurosciences Inc (JUNS), indicating that no earnings forecast score is currently available, while the industry average is 8.10. Based on one analyst, the stock has a "Buy" rating with a target price of 25.000, representing 0.00% …

Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts

Promis Neurosciences (NASDAQ:PMN) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $31.50. Despite this positive outlook, the company reported a quarterly loss of $1.26 per share, missing consensus estimates, and analysts anticipate a full-year loss …

ProMIS Neurosciences Inc (PMN) Stock News Today

This article provides an update on ProMIS Neurosciences Inc (PMN) stock, noting a recent increase of 10.35%, bringing its share price to 14.710 USD. The platform, TradingKey, states that more news, earnings reports, analyst ratings, and key developments for PMN are coming soon. The …

Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares

Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc. (PMN), purchased 2,280 common shares at $13.30 each on August 5, 2026. This open market transaction increased her direct holdings to 6,221 common shares. The filing was classified as neutral in impact and positive in …

Minerva Neurosciences Releases Q2 2026 Financial Results

Minerva Neurosciences (NERV) reported its Q2 2026 financial results, showing a narrower loss of $0.14 per share, an improvement from $0.43 in Q2 2025. The company posted a net income of $17.5M, reflecting progress in managing R&D spending while advancing its CNS therapies. Analysts …

Neuropace Inc (NPCE) Stock News Today

This page from TradingKey provides current stock information for Neuropace Inc (NPCE), including its stock price, market cap, and links to financial data, forecasts, and ownership details. As of the latest update, the stock was trading at $14.830, up 6.69%, with a market cap …

Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity

Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist, as a treatment for obesity. This move signifies the company's entry into the multi-agonist incretin therapeutics market, aiming to address limitations of current GLP-1-based treatments such as gastrointestinal …

Euroseas Ltd expected to post earnings of $4.24 a share - Earnings Preview

Euroseas Ltd (ESEA) is expected to announce earnings of $4.24 per share. This financial projection is based on a Refinitiv report. The article serves as an earnings preview for the company.

EuroDry Ltd (EDRY) Stock News Today

Does Euronet’s Peru SaaS Deal And Share Shelf Filing Reframe Its Software-Led Payments Story (EEFT)?

Euronet Worldwide (EEFT) recently announced a multi-year SaaS agreement with Unibanca in Peru to deploy its CoreCard credit issuing platform and filed a US$152.08 million share shelf registration. This move reinforces Euronet's strategy to shift towards software-based payment solutions, particularly in Latin America, leveraging …

64-year-old luxury giant closes at least 217 stores, plans more

"Luxury goods are the only area in which it is possible to make luxury margins," said Bernard Arnault, CEO of LVMH, the world's largest luxury group behind powerhouses such as Louis Vuitton, Christian Dior, Fendi, and Givenchy. Arnault may be right about margins, but …

Clearpoint Neuro Inc (CLPT) Stock News Today

Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary

Minerva Neurosciences, Inc. reported a net income of $17.47 million for Q2 2026, a significant improvement from a loss in the previous year, with diluted loss per share narrowing to $(0.14). The company initiated its C19 Phase 3 trial for roluperidone, increased R&D spending, …

Minerva Neurosciences: Q2 Earnings Snapshot

Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues

Minerva Neurosciences (NERV) announced a Q2 2026 GAAP net income of $17.5 million. The company's Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia, is ongoing, with topline efficacy data expected in mid-2027 and mid-2028 for its two phases. The report also detailed …

Minerva Neurosciences (Nasdaq: NERV) swings to Q2 profit on warrant gain

Minerva Neurosciences reported a Q2 2026 GAAP net income of $17.5 million, or $0.36 per basic share, primarily due to a $27.6 million non-cash gain from a warrant liability fair value change. Despite this, the adjusted non-GAAP net loss widened to $7.8 million, reflecting …

Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of "Buy" from Analysts

Euroseas Ltd (ESEA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Euroseas Ltd (ESEA) has an earnings forecast score of 8.00, ranking 14th in the Freight & Logistics Services industry. Analysts have set an average price target of $75.00, with most recommending a "Buy" rating. The company's expected revenue for the next quarter is $56.10M, …

Firefly Neuroscience Inc (AIFF) Earnings Forecast: Future EPS & Revenue Growth Estimates

EURO MENKUL KIYMET YATIRIM ORTAKLIĞI A.Ş.(EUYO) Sorumluluk Beyanı (Konsolide Olmayan) 6 Ağustos 2026

Schroder European REIT Requests Shareholder Approval for Managed Wind-Down Strategy

JUNS|Jupiter Neurosciences Inc|Price:5.100|Chg%:-0.533

Coca-Cola Europacific Partners PLC (AMS:CCEP) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Entropy Neurodynamics Director Herwig Janssen Receives Shares in Lieu of Cash Fees

MFE-Mediaforeurope N.V.: analisi fondamentale e valutazioni finanziarie MFEA | NL0015001OI1

Jupiter Neurosciences, Inc. (JUNS) Stock Price, News, Quote & History

Jupiter Neurosciences, Inc. (JUNS) stock was trading at $5.30, down 5.90%, as of 1:45:04 p.m. EDT. The company announced a 1-for-75 reverse stock split effective August 7, 2026. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing therapeutics for central nervous system disorders …

Earnings call transcript: EuroDry Q2 2026 profit jumps as shares rise 7.5%

Entropy Neurodynamics Boosts Director Equity Through Share-Based Fees

Entropy Neurodynamics Issues New Shares in Lieu of Directors’ Fees

Earnings Preview: Neuronetics to Report Financial Results Pre-market on August 11

Neuronetics is scheduled to release its financial results pre-market on August 11. Analysts are anticipating an earnings per share (EPS) of -$0.12, with revenue projected to be around $15.54 million. Investors will be closely watching these figures for insights into the company's performance.

Earnings Preview: NeuroPace to Report Financial Results Post-market on August 11

This article announces that NeuroPace is scheduled to release its financial results after the market closes on August 11. Investors and analysts will be keen to review the company's performance and outlook during the upcoming earnings call.

Promis Neurosciences (PMN) Projected to Post Earnings on Thursday

Promis Neurosciences (PMN) is expected to report its Q2 2026 earnings before market open on Thursday, August 13th, with analysts forecasting a loss of $1.3786 per share. This follows a larger-than-expected loss in the previous quarter. Despite mixed analyst views, the company holds a …

Stoneweg Europe Stapled Trust Climbs Governance Ranks and Secures MSCI ESG ‘AA’ Rating

Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com

This article reports on a Form 8K filing by Jupiter Neurosciences Inc. for August 6th. The content is very brief, mainly consisting of the headline and a reference to Reuters, indicating it's an announcement of the filing rather than an analysis of its contents. …

EuroDry Q2 Earnings Call Highlights

Key Points Interested in EuroDry? Here are five stocks we like better. EuroDry returned to profitability in Q2 2026 as net revenue rose 57% year over year to $17.7 million and net income reached $6.59 million, compared with a $3.1 million loss a year …

EuroDry Ltd. (EDRY) Stock Rises on Q2 2026 Earnings

EuroDry Ltd. (EDRY) reported strong Q2 2026 earnings, with revenue up 56.96% year-over-year to $17.7 million and gross profit soaring by 251.8% to $13.6 million. The company's net income reached $6.6 million, and its stock rose 7.93% following the announcement. Insider trading and hedge …